company background image
P731 logo

Medexus Pharmaceuticals DB:P731 Stock Report

Last Price

€1.63

Market Cap

€52.4m

7D

-1.2%

1Y

59.8%

Updated

16 Mar, 2025

Data

Company Financials +

Medexus Pharmaceuticals Inc.

DB:P731 Stock Report

Market Cap: €52.4m

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Medexus Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Medexus Pharmaceuticals
Historical stock prices
Current Share PriceCA$1.63
52 Week HighCA$3.56
52 Week LowCA$0.98
Beta2.03
1 Month Change-20.87%
3 Month Change-14.21%
1 Year Change59.80%
3 Year Change-25.91%
5 Year Change7.24%
Change since IPO-43.40%

Recent News & Updates

Recent updates

Shareholder Returns

P731DE PharmaceuticalsDE Market
7D-1.2%-0.5%-0.5%
1Y59.8%-13.0%15.5%

Return vs Industry: P731 exceeded the German Pharmaceuticals industry which returned -13% over the past year.

Return vs Market: P731 exceeded the German Market which returned 15.5% over the past year.

Price Volatility

Is P731's price volatile compared to industry and market?
P731 volatility
P731 Average Weekly Movement14.5%
Pharmaceuticals Industry Average Movement4.3%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: P731's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: P731's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a82Ken d'Entremontwww.medexus.com

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Medexus Pharmaceuticals Inc. Fundamentals Summary

How do Medexus Pharmaceuticals's earnings and revenue compare to its market cap?
P731 fundamental statistics
Market cap€52.42m
Earnings (TTM)€3.27m
Revenue (TTM)€100.66m

16.0x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
P731 income statement (TTM)
RevenueUS$109.54m
Cost of RevenueUS$46.13m
Gross ProfitUS$63.41m
Other ExpensesUS$59.85m
EarningsUS$3.56m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.11
Gross Margin57.89%
Net Profit Margin3.25%
Debt/Equity Ratio119.3%

How did P731 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 23:10
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medexus Pharmaceuticals Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity